NEVVI Medicare utilization intelligence
or

← back

Provider profile

FORAN, JAMES MD

Hematology-Oncology · NPI 1992749139 · JACKSONVILLE, FL

1
Groups
56
Codes · 2023
58,722
Disclosed services

FORAN, JAMES is a Hematology-Oncology in JACKSONVILLE, FL, a member of 1 medical group, who billed 56 distinct codes to Medicare Part B in 2023.

Groups: MAYO CLINIC JACKSONVILLE (JACKSONVILLE, FL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2023

58,722
disclosed services
56
codes billed to Medicare Part B

This provider's disclosed Medicare payments across all codes were in CY2023.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2023)

Medicare Part B FFS · CY2023 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J1453 Injection, fosaprepitant, 1 mg
J9299 Injection, nivolumab, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9267 Injection, paclitaxel, 1 mg
J9264 Injection, paclitaxel protein-bound particles, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J9041 Injection, bortezomib, 0.1 mg
J0461 Injection, atropine sulfate, 0.01 mg
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
J9206 Injection, irinotecan, 20 mg
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J2469 Injection, palonosetron hcl, 25 mcg
J9190 Injection, fluorouracil, 500 mg
99213 Established patient office or other outpatient visit, 20-29 minutes
J0640 Injection, leucovorin calcium, per 50 mg
J9045 Injection, carboplatin, 50 mg
36591 Collection of blood sample from implanted device
99212 Established patient office or other outpatient visit, 10-19 minutes
J3480 Injection, potassium chloride, per 2 meq
J3475 Injection, magnesium sulfate, per 500 mg
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J7030 Infusion, normal saline solution , 1000 cc
96372 Injection of drug or substance under skin or into muscle
96361 Infusion into a vein for hydration, each additional hour
96415 Administration of chemotherapy into vein, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J9060 Injection, cisplatin, powder or solution, 10 mg
99214 Established patient office or other outpatient visit, 30-39 minutes
J1200 Injection, diphenhydramine hcl, up to 50 mg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J3489 Injection, zoledronic acid, 1 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99215 Established patient office or other outpatient visit, 40-54 minutes
96360 Infusion into a vein for hydration, 31-60 minutes
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99238 Hospital discharge day management, 30 minutes or less
99205 New patient office or other outpatient visit, 60-74 minutes
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96374 Injection of drug or substance into vein
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
96411 Administration of additional new drug or substance into vein using push technique
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.